Minicircle DNA Vaccine Purification and E7 Antigen Expression Assessment

Area of Science:

• Biotechnology
• Vaccinology
• Molecular Biology

Background:

• Human papillomavirus (HPV) oncoprotein E7 drives cervical cancer by inhibiting tumor suppressor pRB.
• DNA vaccines offer preventive and therapeutic strategies against viral infections like HPV.
• Minicircle DNA (mcDNA) shows promise as a next-generation non-viral vector, surpassing plasmid DNA (pDNA) in expression efficiency and biosafety.

Purpose of the Study:

• To establish a robust protocol for producing and purifying supercoiled E7-mcDNA vaccine.
• To evaluate the purity of the manufactured mcDNA vaccine according to regulatory standards.
• To confirm the expression of the E7 antigen from the purified mcDNA vaccine.

Main Methods:

• Production of supercoiled E7-mcDNA.
• Purification of mcDNA using size-exclusion chromatography.
• Assessment of E7 antigen expression via immunocytochemistry.

Main Results:

• Successfully produced and purified supercoiled E7-mcDNA vaccine.
• Achieved high purity levels for mcDNA meeting regulatory criteria.
• Confirmed successful expression of the E7 antigen.

Conclusions:

• The described methodology provides a reliable approach for manufacturing high-purity E7-mcDNA vaccines.
• This mcDNA vaccine platform holds potential for cervical cancer prevention and therapy.
• Further development can advance the clinical application of mcDNA-based HPV vaccines.